Handa Pharmaceuticals (ROCO:6620) Moat Score: 0/10 (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6620 Handa Pharmaceuticals Inc ROCO:6620
75 GF Score
Price NT$84.70
GF Value NT$183.95
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Handa Pharmaceuticals Moat Score?

Handa Pharmaceuticals has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Handa Pharmaceuticals has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Handa Pharmaceuticals might have No Moat - No discernible moat.

Handa Pharmaceuticals  (ROCO:6620) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Handa Pharmaceuticals Moat Score Related Terms

ROCO:6620
75GF Score
Handa Pharmaceuticals Inc ROCO:6620
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Handa Pharmaceuticals (ROCO:6620) Overvalued in 2026?

Based on GuruFocus' analysis, Handa Pharmaceuticals stock appears to be undervalued. The current stock price of NT$84.70 is trading 54% below its estimated GF Value™ of NT$183.95. GuruFocus considers Handa Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for ROCO:6620:

  • Moat Score: 0
  • GF Value™: NT$183.95 vs. price of NT$84.70 (54% below fair value)
  • GF Score™: 75/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6620 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Handa Pharmaceuticals Business Description

Address Nanke 3rd Road, 3F-1,3F-2, No.23, Xinshi Dist, Tainan, TWN, 74147
Handa Pharmaceuticals Inc is a Taiwan-based specialty pharmaceutical company. It is engaged in the development of niche drugs. The company focuses on the development of high-barrier/patentable niche products.
75GF Score

Get the complete analysis for ROCO:6620

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$84.70
Price
NT$183.95
GF Value